Donepezil Hydrochloride
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dementia With Lewy Body Disease
Conditions
Dementia With Lewy Body Disease
Trial Timeline
Apr 20, 2015 → Mar 30, 2017
NCT ID
NCT02448784About Donepezil Hydrochloride
Donepezil Hydrochloride is a pre-clinical stage product being developed by Eisai for Dementia With Lewy Body Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02448784. Target conditions include Dementia With Lewy Body Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02448784 | Pre-clinical | Completed |
| NCT02162264 | Pre-clinical | Completed |
| NCT02162251 | Pre-clinical | Completed |
| NCT01251718 | Pre-clinical | Completed |
| NCT01129596 | Pre-clinical | Completed |
| NCT00477659 | Approved | Completed |
| NCT00165750 | Approved | Terminated |
| NCT00165724 | Approved | Completed |
| NCT00165737 | Phase 3 | Completed |
| NCT00165659 | Phase 2 | Completed |
| NCT00096473 | Phase 3 | Completed |
Competing Products
20 competing products in Dementia With Lewy Body Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 3 | 69 |
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| IGC AD1 + Placebo | IGC Pharma | Phase 1 | 25 |
| E2020 + Placebo | Eisai | Approved | 85 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Rasagiline | Eisai | Phase 2 | 52 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo | Eisai | Phase 3 | 77 |
| E2020 + E2020 | Eisai | Phase 2 | 52 |
| donepezil hydrochloride (Aricept) | Eisai | Approved | 85 |
| 3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 52 |
| E2020 + E2020 | Eisai | Phase 3 | 77 |
| Irsenontrine + Placebo | Eisai | Phase 2 | 52 |
| E2020 | Eisai | Phase 2 | 52 |
| Mecobalamin | Eisai | Approved | 85 |
| E2020 + Placebo | Eisai | Phase 3 | 77 |
| Donepezil Hydrochloride | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |